Our Product
Agulcator® for Type 2 Diabetes
Dr. Gorgani has identified that adjunctive intake of particular derivative of inulin improved both typical diabetes biomarkers and quality of life in a patient with type 2 diabetes taking sulphonylurea medications.
After long term clinical case studies and a clinical trial, two international patents were granted, covering over 65% of global diabetes population.
Over a decade of refinements our first product, Agulcator®, has now been launched in Australia.
Agulcator® is supplied as a Food for Special Medical Purpose; it may provide beneficial effects and therefore medical professional will be required to help best manage type 2 diabetes patient’s medication regimes.
Only Health Care Professionals can order Aglucator®. Please visit aglucator.com.au to order.
Our Company
A goal-oriented and accomplished company
OzStar Therapeutics received two Commercialisation Australia Government grants to conduct commercial and regulatory due diligence on its technology and to conduct a phase 2 clinical trial, both of which have been completed successfully.
Our mission is to provide an add-on prebiotic that may stabilise some aspects of diabetes condition in sulphonylurea treated diabetics.
Our vision is to make our first product Agulcator® the number one Prebiotic for type 2 diabetics on sulphonylureas.
Dr. Nick N Gorgani, BE, MBBS, MS Drug Dev, Phd
Founder, President and CEO of OzStar Therapeutics Pty Ltd
Our Values
We Believe in Perseverance and Unmatched Science
01.
Innovation
Through the conduct of world-class research for over a decade our team has discovered a novel approach that may assist in stabilising some aspects of diabetes.
Over a decade of relentless R&D efforts, we have specifically developed Agulcator® to effectively balance gut microbiome in individuals with diabetes to better manage their condition, supporting the proven effectiveness of sulphonylurea class of anti-diabetes drugs.
02.
Teamwork
Built from seasoned, highly experienced, and dedicated directors, executive team, and scientific/medical advisory board members, OzStar Therapeutics aspires to be one of the world’s best pharmaceutical companies.
03.
Sustainable
OzStar Therapeutics is proud to own a novel technology that has the potential to serve people with type 2 diabetes on sulphonylurea class drugs.
Adjunctive intake of Agulcator® specifically increases the gut microbes that are reduced by chronic intake of sulphonylurea drugs (derivatives of sulfa drugs) to help stabilise some aspects of diabetes.
04.
Integrity
Directors, executive team, and advisory members of OzStar Therapeutics are eminent individuals who have contributed enormously to the field of their expertise with integrity and respect.
05.
Excellence
By helping to stabilise some aspects of diabetes, Agulcator® may have the potential to provide a better quality of life for diabetics on sulphonylureas.
06.
Commitment
OzStar will relentlessly continue until Agulcator® is being utilised by hundreds of millions of people with type 2 diabetes taking sulphponylurea class drugs.
Our Products
Committed to Quality, Safety and Sustained Effectiveness
Clinical Development
OzStar Therapeutics conducted several long-term clinical case studies and an Australian Government-backed clinical trial that showed an effective adjunct to sulphonylurea treated type 2 diabetics.
Regulatory & Access
Through rigorous due diligence, OzStar Therapeutics fulfilled all requirements to launch its first-in-class product Agulcator® in Australia as Food for Special Medical Purpose.
Intellectual Properties and Trademarks
Within the past 14 years, OzStar Therapeutics received two families of patents granted in 14 countries with the majority of these having the highest numbers of people with type 2 diabetes on sulphonylurea class drugs. OzStar Therapeutics also obtained a trademark for Agulcator®.
Scientific Exchange
At OzStar Therapeutics we are committed to contributing to the scientific community we engage with. Our clinical trial results were presented at the European Association for the Study of Diabetes (EASD). Subsequently, these results were peer-reviewed and published in an international journal. The OzStar team has also published a review article describing the benefits of the adjunct intake of prebiotics such as Agulcator® in medicinal therapies. OzStar CEO has since been invited as a keynote speaker at several related international conferences.
Our Purpose
To serve people with type 2 diabetes who deserve more stable condition.
Type 2 diabetes is a chronic progressive disease and this results in reduced effectiveness over time of several currently available treatments.
You may ask:
- What is the main driving force (aetiology) behind the development and progression of type 2 diabetes?
- Why do currently marketed drugs commonly lose effectiveness?
We have plenty of emerging scientific information to share with you. Click Health Care Professionals
Our Brands
